Abstract
The rise of generics, products at risk and defence strategies
The figures speak for themselves. Of the 150 products detailed in this report,
24 faced generic competition in 2006. This rose to 35 in 2007 and 49 in 2008.
By 2012, this will have risen to 73 products on a conservative estimate, and
possibly as many as 91.
When is patent protection not patent protection?
Often when it is a pharmaceutical product. At one time the extensive use of
patents safeguarded a branded company' s product portfolio against generic
competition. Increasingly, however, the fiercely competitive US generic sector
has pursued an aggressive policy of earlier and earlier challenges. Compelled
by the need for new revenues in the world' s largest pharmaceutical market, and
often with the tacit encouragement of cost-conscious health payers, the sector
has been buoyed by many successful legal and regulatory decisions well ahead
of patent expiry.
In response, the branded industry has employed a range of mechanisms to stop
or limit the generics companies' ambitions - with varying success. Traditional
defence of right through litigation is a strategy that has been joined by the
rise of authorised generics, incremental innovation and the introduction of
combination therapies.
The issue has never been more critical. Over the next 5 years over 73 products
- including the current leading therapies - will face generic competition with
a significant influence on sales, profitability and R&D investment.
A unique business analysis of this crucial issue
At this critical stage, everyone - be they a branded manufacturer, generics
company or commercial investor - needs to understand in detail which products
are affected and the mounting effect it will have on the leading
pharmaceutical companies. This new 188-page report, written by leading generic
market analyst Andy Crofts, compares and contrasts at the product level the
current situation and looks at how the market will develop to 2012. Packed
with facts, figures and novel analysis, this report is essential reading for
all senior executives throughout the industry.
This extensive report provides a unique analysis of the likely impact of generic competition in the US pharma market. Now you can...
- Identify the 150 products which could be subject to generic competition
over the next 5 years
- Evaluate the level of impact on each product
- Assess the impact of generic competition on 14 leading branded companies
- Understand the strategies being used by companies in defence of their
products' position
View Cart
